The Rb-E2F axis is an important pathway involved in cell-cycle control that is deregulated in a number of cancers. E2f transcription factors have distinct roles in the control of cell proliferation, cell survival and differentiation in a variety of tissues. We have previously shown that E2fs are important downstream targets of a CSF-1 signaling cascade involved in myeloid development. In cancer, tumorassociated macrophages (TAMs) are recruited to the tumor stroma in response to cytokines secreted by tumor cells, and are believed to facilitate tumor cell invasion and metastasis. Using the MMTV-Polyoma Middle T antigen (PyMT) mouse model of human ductal carcinoma, we show that the specific ablation of E2f3 in TAMs, but not in tumor epithelial cells, attenuates lung metastasis without affecting primary tumor growth. Histological analysis and gene expression profiling suggest that E2f3 does not impact the proliferation or survival of TAMs, but rather controls a novel gene expression signature associated with cytoskeleton rearrangements, cell migration and adhesion. This E2f3 TAM gene expression signature was sufficient to predict cancer recurrence and overall survival of estrogen receptor (ER)-positive breast cancer patients. Interestingly, we find that E2f3b but not E2f3a levels are elevated in TAMs from PyMT mammary glands relative to controls, suggesting a differential role for these isoforms in metastasis. In summary, these findings identify E2f3 as a key transcription factor in TAMs, which influences the tumor microenvironment and tumor cell metastasis.
INTRODUCTION
Breast cancer is the second leading cause of cancer mortality in women with approximately 30% patients eventually developing metastasis. 1 Metastasis is a complex process during which tumor cells colonize distant organ sites. 2, 3 Metastasis contributes to 90% of deaths from solid tumors and displays diverse clinical manifestations. 4 The tumor stroma or microenvironment has a crucial role in the dissemination of tumor cells from the primary cancer. Tumor stroma is composed of extracellular as well as cellular constituents, including fibroblasts, endothelial and immune cells. During tumor progression, the tumor stroma may be altered to influence the neoplastic properties of tumor cells and facilitate their dissemination. 4, 5 One of the extreme examples of how stromal cells can drive tumorigenesis was shown by Kim et al. 6 where selective deletion of Smad4 in T cells resulted in formation of epithelial cancer in the gastrointestinal tract of mice.
The initial response of immune cells in cancer is to recognize and destroy tumor cells. However, strategies in tumor cells to escape, suppress immune destruction or convert immune cells to have pro-tumorigenic roles often evolve. 7 Tumor-associated macrophages (TAMs) are recruited to the tumor stroma in response to cytokines secreted by both tumor epithelial cells and other resident stromal cells. 5, 8 In addition, TAMs also activate myofibroblasts to secrete cytokines that help in the recruitment of endothelial progenitor cells and promote neovascularization. 9 Clinical studies show that infiltration of TAMs correlates with poor prognosis in a variety of cancers 10, 11 and that therapeutic strategies to limit macrophage numbers are effective at decreasing cancer development. 12 Similarly, depletion of macrophages using pharmacological agents, such as clodronate, reduces tumor angiogenesis and metastasis in various mouse models of cancer. [13] [14] [15] Colony stimulating factor 1 (CSF-1) secreted by tumor cells facilitates the recruitment of TAMs, which in turn promote the invasion and migration of tumor cells by the secretion of EGF. 16 Mice lacking the CSF-1 ligand (op/op) have reduced incidence of pulmonary metastasis. 17 In human breast cancer, overexpression of CSF-1 correlates with poor prognosis and dense leukocyte infiltration. 18 The engagement of the CSF-1 receptor by CSF-1 leads to the activation of numerous signaling cascades during normal myeloid development, including the Rb/E2f pathway, which is involved in regulating cell proliferation, survival and differentiation. 19 Genetic alterations of RB have been reported in approximately 20-30% of breast cancers. 20, 21 RB exerts its tumor suppressive effects through the regulation of E2F transcription factors. 22 Increased E2F3 expression has been reported in prostate, ovarian and lung cancers [23] [24] [25] [26] and amplification of 6p22, which includes the E2F3 locus, has been observed in bladder cancer. 25 Introduction of miR-148a and miR-34b/c in tumor cells target E2F3 and result in a reduction of tumor growth and metastasis. 27 Collectively, these studies imply that E2F3 is frequently overexpressed or amplified in a number of cancers and that its reduction may deter cancer progression.
We have previously shown that E2fs are important downstream targets in CSF-1 signaling cascade involved in macrophage development. 19 However, the role of E2f3 in the tumor microenvironment (stroma) remains to be investigated. Here, we address the potential role of E2f3 in TAMs during mammary tumorigenesis. To this end, we examined the consequence of ablating E2f3 in either TAMs or tumor cells on tumor progression 1 and lung metastasis using the MMTV-Polyoma Middle T antigen (MMTV-PyMT) mouse model of breast cancer. We show that the loss of E2f3 in tumor macrophages, but not in mammary tumor cells, leads to the attenuation of lung metastasis without affecting the growth of the primary tumor.
RESULTS

Loss of one copy of E2f3 reduces lung metastasis
To investigate the role of E2f3 during mammary gland tumorigenesis in mice, we used the MMTV-PyMT model of breast cancer. The advantage of this model is that there is rapid tumor progression accompanied by immune infiltration and lung metastasis. We generated PyMT;E2f3 +l+ (n = 36) and PyMT;E2f3 +/ − (n = 19) female mice to determine whether the loss of one E2f3 allele would affect tumor growth and metastasis. Mice were palpated twice a week, and time to tumor was recorded once the tumor volume reached 5mm 3 . Kaplan-Meier plots show that loss of one copy of E2f3 had no effect on the timing of tumor onset (Figure 1a ) or tumor burden (Figure 1b) , suggesting that loss of a single E2f3 allele does not affect tumor development by the PyMT oncogene. Moreover, histopathological analysis of tumors isolated from PyMT;E2f3 +/+ and PyMT;E2f3 +/ − mice revealed no gross pathological differences between the two groups of mice ( Figure 1c ). However, examination of lungs at end stage showed a significant reduction of metastasis in PyMT;E2f3 +/ − mice (Figures 1d and e) . During the course of this study, we also examined metastasis to the bone, spleen and liver of PyMT;E2f3 loxp/loxp and PyMT;E2f3 loxp/loxp mice and found no signs of metastasis at these sites.
Since E2f3 null mice are not viable, we used a conditional E2f3 allele and a bitransgenic system where the expression of Cre is under the control of the mouse mammary tumor virus promoter (MMTV-rtTa;teto-Cre) to specifically ablate E2f3 in the mammary ductal epithelium. Two cohorts of female mice were generated (PyMT;E2f3 loxp/loxp ;MMTV-rtTa and PyMT;E2f3 loxp/loxp ;MMTV-rtTa;tetoCre) and fed with food containing doxycycline (1 mg/kg). Surprisingly, ablation of E2f3 in PyMT; E2f3 loxp/loxp ;MMTV-rtTa; teto-Cre mice resulted in a slight but significant delay in tumor initiation (P o0.003), but had little impact on tumor burden and metastasis to the lungs (Supplementary Figure S1A and C). Examination of mammary glands revealed no change in tumor cell proliferation or macrophage infiltration between the two cohorts of mice (Supplementary Figure S1D) . Together, these results suggest that the reduction of lung metastasis initially observed in PyMT; E2f3 +/ − mice may be mediated through a cell nonautonomous mechanism.
E2f3 ablation in TAMs leads to the reduction of lung metastasis Macrophages are an important constituent of tumor stroma and have been shown to be important in tumor cell dissemination during metastasis. 4, 5 Given that global deletion of one allele of E2f3 led to a decrease in lung metastasis, we entertained the hypothesis that E2f3 in macrophages may contribute to metastasis in mice. To test this hypothesis we used the Lysozyme Cre (LysCre) transgene to conditionally inactivate E2f3 in macrophages and compare tumor growth and metastasis in PyMT;LysCre;E2f3 loxp/loxp , PyMT;LysCre; E2f3 +/loxp and PyMT;E2f3 loxp/loxp mice. PCR genotyping of macrophages isolated from tumors and lungs showed that Cre expression resulted in deletion of E2f3, albeit not in one hundred percent of cells (Figure 2a) .
Although the tumor burden in the three cohorts of mice was similar (Figures 2b and c Figure  S4) . 28 Together, these results suggest that E2f3 ablation in TAMs results in a significant reduction of lung metastasis without affecting mammary development or tumor initiation and growth. Loss of E2f3 leads to disruption of cell adhesion and cytoskeleton genes To explore the underlying molecular mechanism by which E2f3 in macrophages promote lung metastasis, we analyzed global gene expression in control and E2f3-deleted TAMs using an Affymetrix platform. To this end, RNA from F4/80 + TAMs collected from PyMT; E2f3 loxp/loxp (control) and PyMT; LysCre; E2f3 loxp/loxp mice was processed and used to query mouse Affymetrix 430 2.0 oligoarrays. An unbiased method similar to Gene Set Enrichment Analysis 29 was used to identify genes that were differentially expressed between the two groups. Surprisingly, the majority of the 104 differentially expressed genes were upregulated in the E2f3-deleted TAMs compared with controls (41.5-fold, P o 0.001; Figure 6a ). Quantitative real-time (RT-PCR) expression analysis confirmed the increased levels of a subset of these mRNAs in E2f3-depleted TAMs (Figure 6b ). Gene ontology of differentially expressed genes showed an enrichment of gene functions related to cell migration, adhesion, cytoskeleton and signaling networks and a conspicuous absence of cell cycle-related functions ( Figure 6c and Supplementary Table 1) .
The matricellular proteins (Sparcl1, Jam2 and Fbln5) participate in the assembly and stabilization of extracellular matrix structures and are involved in cell adhesion and migration. Their expression has been found to be downregulated in a number of cancers. [30] [31] [32] Our microarray and RT-PCR data showed increased expression of these genes in E2f3-deleted TAMs, suggesting that their increased expression may lead to reduced migration of tumor cells. On the basis of these findings, we evaluated whether deletion of E2f3 in TAMs might impair tumor cell migration. Migration assays were performed using MVT-1 cells and conditioned media collected from TAMs of PyMT;E2f3 loxp/loxp (control) and PyMT;LysCre;E2f3 loxp/loxp mice. These assays showed a significant reduction in tumor cell migration (Po 0.0001) when conditioned media from E2f3-ablated TAMs was used ( Figure 6d and Supplementary Figure S5A ). Sequence analysis of gene promoters revealed that 51 out of the 104 differentially expressed genes contained consensus E2F binding sites within 1 kb from the transcriptional start site, and 14 of the 51 putative target promoters had E2F consensus sites that were conserved between mouse and human (Figure 6e ). Analysis of a subset of these using chromatin immunoprecipitation (ChIP) assays and F4/80 + sorted TAMs from tumors showed E2f3 directly bound to these conserved gene promoters (Figure 6f and Supplementary Figure S5B) .
The E2f3 locus encodes two isoforms, E2f3a and E2f3b, whose expression is driven by distinct promoters. 33 Based on their expression pattern during the cell cycle and their ability to physically interact with Rb, it was suggested that E2f3a may function as a transcriptional activator and E2f3b as a transcriptional repressor. 34 Interestingly, RT-PCR gene expression analysis on FACS sorted F4/80 + macrophages showed that E2f3b levels were significantly upregulated in TAMs relative to normal macrophages, whereas E2f3a expression was unchanged (Supplementary Figure S6) . From these experiments, we conclude that E2f3b expression in macrophages is responsive to tumor cells. Although the individual roles of E2f3a and E2f3b remain to be determined, the fact that both isoforms are deleted in PyMT; LysCre;E2f3 loxp/loxp mice may suggest that E2f3b may have a specific function in the repression of TAM-related gene expression.
E2f3 TAM gene signature predicts good prognosis in breast cancer patients To determine the relevance of these findings to human breast cancer, we used the E2F3-related TAM gene expression signature identified in Figure 6a to query previously published global expression profiles derived from laser-captured tumor stroma (49samples) and adjacent normal stroma (52 samples) in breast cancer patients. 35 The 104-gene signature derived from mouse E2f3-deficient TAMs was able to perfectly segregate normal from tumor stroma (Figure 7a) . Many of the genes in this signature were expressed at higher levels in normal stroma when compared with tumor stroma (Supplementary Table 2 ), consistent with lower levels of E2F3 expression in the normal stroma compartment (P o 0.015; data not shown).
To determine whether the E2F3 TAM gene signature correlated with clinical outcome, we used unsupervised clustering of expression data obtained from four independent breast cancer patient data sets. The comparison of mouse E2f3 TAM gene signature with human breast cancer patient data sets (Finak, NKI, Stockholm and Wang) predicted a significant better overall survival (P o0.05) (Figure 7b ). Because the NKI and Wang data sets have a large cohort of estrogen receptor (ER)-positive and ERnegative breast cancer patients, we queried these two patient subsets independently. This analysis shows that the E2f3 mouse gene signature predicted good prognosis in ER-positive, but not in Figure S7) . From these results, we conclude that the E2f3 TAM gene signature identified in E2f3-deleted macrophages is represented within normal stroma and is associated with favorable clinical outcome in breast cancer patients.
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DISCUSSION
The Rb-E2F axis represents an important pathway involved in cellcycle control that is disrupted in cancer. 36 Alterations in RB or components that regulate the RB pathway occur in the majority of cancers, including breast cancer. 20, 21 Recent studies have demonstrated the involvement of E2Fs in driving Her2/Neu-and Mycinduced mammary tumorigenesis in mice. 37 However, the role of E2f3 in tumor stroma during cancer progression and metastasis remains to be investigated. Using a PyMT mammary cancer model, we show here that specific ablation of E2f3 in TAMs attenuates lung metastasis without having a major effect on the growth of the primary tumor.
Increased E2F3 expression has been observed in human prostate, ovarian and lung cancers. [23] [24] [25] In a mouse model of thyroid cancer, a role for E2f3 has been implicated in the metastasis of tumor cells to the liver and lung, 38 however, whether cell autonomous or non-autonomous mechanisms were at play was not determined. Using conditional knockout approaches, we show that ablation of E2f3 in TAMs results in decreased pulmonary metastasis without affecting the growth of the primary tumor, suggesting that E2f3 in the tumor stroma has an important cell non-autonomous role in promoting the metastatic potential of tumor cells.
The E2F family of transcription factors is conserved from nematodes to mammals, with three genes encoding one activator and two repressors in C. elegans and eight genes encoding three activators and five repressors in humans. 39 E2Fs were identified as factors that control the cell cycle, apoptosis, differentiation and stress responses; thus, E2Fs have been bestowed with a role as master regulators of cell proliferation. 22 Studies in flies, worms and mice support a role for E2Fs beyond cell-cycle control. For example, loss-of-function studies identified roles for lin-35 (RB1 ortholog) and efl-1 (E2F1-3 ortholog) in epidermal growth factormediated cell fate determination in C. elegans during vulval development. 39 Additional roles for mammalian E2Fs in angiogenesis, adipogenesis and cell migration have also been described. [39] [40] [41] The E2f3 locus encodes two isoforms, E2f3a and E2f3b, whose expression is driven by distinct promoters. 33 Previous studies from the Tlsty laboratory show that inactivation of Rb pathway and elevated E2f3 expression are characteristic features of basal-like cancer. 42 A recent study from our laboratory has shown increased E2f3a expression in tumor cells overexpressing the Erb2/Her2 oncogene. 37 Consistent with these findings, we show here that deletion of E2f3 in the mammary epithelium of PyMT mice also delays tumor onset, suggesting that the E2f3a isoform may have oncogenic functions, likely through promoting cell proliferation and cell survival, in a number of mammary tumor models. Whereas E2f3a is highly expressed in tumor cells, we observe that E2f3b is highly expressed in TAMs. We find that E2f3 in TAMs directly binds to regulatory sequences of a number of genes that negatively regulate tumor cell metastasis. The expression of these genes in TAMs is increased upon the loss of the E2f3 allele. Thus, we suggest that E2f3b is the likely isoform encoded by the E2f3 locus that functions as a transcriptional repressor in TAMs to promote metastasis. Because the Cre-mediated ablation of the E2f3 floxed allele used here and in previous studies results in deletion of both E2f3 isoforms, the relative contributions of each isoform during tumorigenesis remain to be rigorously determined. In the present study, we show that E2F3 controls a gene expression signature associated with cytoskeletal rearrangements and cell adhesion. Surprisingly, E2f3 ablation in TAMs had no effect on their proliferation nor in the expression of cell cycleregulated genes. It is well recognized that the extra cellular matrix is not simply a scaffold for tumor cells but instead provides critical signals that affect tumor cell growth, survival and migration. 43 For instance, one of the proteins that promote extra cellular matrix deposition is secreted protein acidic and rich in cysteine (Sparc). The absence of Sparc is associated with decreased collagen deposition, and Sparc −/ − mice have enhanced tumorigenesis. 43, 44 Importantly, it was shown that Sparc produced by host leukocytes, rather than tumor cells, promotes the assembly and function of tumor-associated stroma through the organization of collagen type IV. 45 Similarly, Jam2, Fbln5 and Sparcl1 are matricellular proteins that participate in the assembly and stabilization of extracellular matrix structures involved in cell adhesion and migration. The expression of these genes is downregulated in a number of human malignancies. 30, 31 The role of these proteins in inhibiting the migration of cancer cells is well documented. 43, 46 However, the cells that produce these factors and the mechanisms involved in their gene regulation remain poorly understood. We find that ablation of E2f3 in TAMs leads to increased expression of Jam2, Fbln5, Col18A1, Sparcl1 and other secreted factors with roles in cell migration and adhesion, which are known to impede migration of tumor cells. Consistent with the upregulation of this secretory cell adhesion signature in E2f3-deficient TAMs, analysis of the Finak stroma-specific data set 35 revealed that expression of this signature was downregulated in tumor stroma relative to normal stroma. This gene signature also predicted better survival outcomes in the Finak, NKI, Wang and Stockholm data sets. 35, [47] [48] [49] We would thus suggest that elevation of E2f3b expression and repression of this secretory cell adhesion signature in TAMs may have a role during tumor progression and metastasis in breast cancer patients.
MATERIALS AND METHODS
Mammary tumor models
All animals used in the study were fifth-generation FVB/N background. Mice carrying PyMT oncogene under control of MMTV promoter were used in this study. Macrophage-specific deletion of E2f3 f/f was achieved by breeding them with the mice carrying Cre recombinase driven by the lysozyme promoter (LysCre). 50 To delete E2f3 loxp/loxp in mammary epithelial cells, mice were bred with MMTV-rtTA;teto-Cre mice. Induction of the MMTV-rtTA/teto-Cre system was achieved by administration of doxycycline in food (1 mg/kg) at 4 weeks of age and continued until the animals were killed. Mice were palpated twice a week for tumors, they were considered as tumor free until the tumors were 5mm. Mice were killed when they were 110 days old or reached early removal criteria. Genotyping was performed on genomic DNA isolated from tail clips of the mice. All the studies were conducted under the guideline of ULAR at Ohio State University.
Orthotropic injections
Briefly, 2 × 10 5 MVT-1 cells were injected either through the tail vein or subcutaneously into the fat pad of 8-to 10-week-old E2f3 loxp/loxp and LysCre; E2f3 loxp/loxp female mice. Mice were killed 2-4 weeks after the injection.
Histology and IHC
For whole-mount staining of mammary glands, inguinal gland #4 or #9 was removed, fixed in Carnoys fixative at 4°C overnight, rehydrated and stained with Carmine Red. Tumors and lungs removed from the mice were fixed in 10% buffered formalin and embedded in paraffin. To quantify metastatic foci in the lungs, each lobe was sectioned and stained with hemotoxylin and eosin (H&E). Image J software (Image J, NIH, Bethesda, MD, USA) was used to quantify the metastatic area in each lobe of the lung. For H&E and IHC staining, 5 μm sections were cut, deparaffinized in xylene and rehydrated 
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Plcb4 with graded ethanol series. The tumor and lung sections were then stained with α-F4/80 (Invitrogen, Carlsbad, CA, USA; MF-48004) or α-Ki67 (Pharmingen, Carlsbad, CA, USA; 550609) antibodies as described below. All primary and secondary antibodies were diluted in DAKO diluent (DAKO, Carpinteria, CA, USA). Sections were blocked with M.O.M. blocking reagent (Vector Labs, Burlingane, CA, USA) for 30 min and incubated with primary antibody for 30 min. The sections were rinsed and incubated with a biotinylated secondary antibody for 15 min. Following the biotinylated secondary antibody, the streptavidin-Alexa dye conjugate was applied for 15 min. Sections were washed for 5 min with phosphate-buffered saline before incubating with DAB for 2 min. Sections were washed in water and counter stained using Meyers hematoxylin followed by a brief rinse in DI water and mounted using Gel/Mount (Biomed, Foster City, CA, USA).
Image analysis
Images of histological and IHC sections were taken with Axio digital camera (Zeiss, Thornwood, NY, USA) mounted on the Axioskop microscope (Zeiss). Whole-mount images were taken with a Coolpix 5700 digital camera (Nikon, Melville, NY, USA). Image files were processed using AxioVision 4.3 software (Zeiss).
Flow cytometry
Tumors harvested from the mice were minced and digested with collagenase. Single-cell suspensions were prepared after passing through a 40-μm mesh and stained with fluorochrome-conjugated F4/80 antibody (Invitrogen, MF48020). After staining, the cells were sorted using FACS Aria (Becton Dickinson, BD, San Jose, CA, USA).
Microarray analysis F4/80
+ TAMs were isolated from tumor samples by FACS as described above. Four independent samples from each genetic group were used for analysis by Affymetrix microarray. RNA was isolated using TRIzol reagent. RNA was then subjected to purification and processed for hybridization to Affymetrix Mouse Genome 430 2.0 Arrays (Santa Clara, CA, USA). Expression values were normalized and log transformed using RMAExpress, normalized data were then analyzed using BRB-ArrayTools 3.7.0. Differentially expressed genes that increased or decreased at P o 0.001 in PyMT;LysCre;E2f3 loxp/loxp samples relative to control samples were used to generate the heatmaps. The microarray data were deposited with GEO (Gene Expression Omnibus) and can be viewed at http://www.ncbi.nlm. nih.gov/geo/ GSE67081.
Real-Time RT-PCR
RNA was isolated using Trizol reagent from F4/80 + TAM. Reverse transcription of total RNA was performed using Superscript III reverse transcriptase (Invitrogen) and RNAse Inhibitor (Roche, Penzberg, Germany) according to the manufacturer's protocol. Real-time PCR was performed using a BioRad iCycler (BioRad, Hercules, CA, USA) and reactions were performed in triplicate and relative amounts of cDNA were normalized to RPL4.
Migration assay
TAMs were isolated from mammary tumors of PyMT;E2f3 loxp/loxp (control) and PyMT;LysCre;E2f3 loxp/loxp mice as described above. After FACS sorting, TAMs were plated in 6-well plates in serum-free media overnight following which the conditioned media was collected and used for the migration assay. Transwell inserts containing 1 × 10 5 MVT-1 cells were placed in 24-well plates containing conditioned media obtained from TAMs. The migration of MVT-1 cells was allowed to proceed overnight. The inserts were stained using the standard protocol following the manufacturer's instructions. Images were acquired using Nikon microscope, and number of cells were quantified using Image J software (Image J, NIH).
ChIP assays
For ChIP assays, F4/80 + TAMs were crosslinked and chromatin was sonicated to an average size of 200-1000 bp. Lysates were subsequently pre-cleared with Salmon Sperm DNA/Protein G agarose slurry. Antibodies specific to α-E2F3 (2 μg, SC-878) were then added to each sample and incubated overnight at 4°C. Antibody-protein-DNA complexes were recovered by addition of Salmon Sperm DNA/Protein G agarose slurry after incubation for 1 h at 4°C. Following extensive washing, the complexes were eluted and decrosslinked at 65°C for 4 h. Finally, samples were treated with Proteinase K (Roche), RNase A (Roche) and purified through Qiaquick columns (Qiagen, Gaithersburg, MD, USA). Real-time PCR quantification of immunoprecipitated DNA was performed using the Biorad iCycler (Biorad) with primers specific for the indicated promoter regions. Sequences for the primers used are available upon request.
Human stroma heat map
Analysis of the mouse E2f3 TAM microarray data led to the identification of 104 differentially expressed unique genes. These genes were queried against a published human breast stroma microarray data set (GSE4823, henceforth referred as Finak data set), which is publicly available and accessible through the NCBI GEO website. A heat map was generated using these genes on the Finak human stroma data set (52 normal stroma and 49 tumor stroma samples) using hierarchical clustering with Euclidean distance measures.
Survival analyses of breast cancer patient cohorts
A Cox proportional hazards model is applied to predict an outcome for each patient from the gene expression of the human orthologs that correspond to differentially regulated genes from mouse E2f3 TAMs. The patients are then split into two groups (high-risk and low-risk patients) and displayed in a Kaplan-Meier plot. A log-rank test was applied to evaluate statistical significance between the two groups. Details are provided in the Supplementary methods.
Statistical analyses
Data are expressed as mean ± s.d. Statistical significance was determined using ANOVA and Wilcoxon rank-sum tests.
